← boardnext 2026-11next 2027-08
KPRX
Kiora Pharmaceuticals, Inc.distress 5/10 · elevated risk$2.530%today-20% from 52w high
Lead: Retinitis Pigmentosa
Revenue
pre-revenue
Liquidity
$14M
Runway
1.3 yrs
Shares 1y
+29%
Price & events
+14.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+2.0%
1W
+2.4%
1M
+3.7%
3M
+14.5%
6M
-16.5%
1Y
-45.0%
2Y
-99.8%
5Y
-99.9%
All
Overview
- Market Cap
- $11.21M
- Volume
- 2.10K
- 52 Week Range
- $1.80 – $3.18
- Total Shares
- 4.43M
- Float Shares
- 4.30M
- Short %
- 0.17%
- % Held by Insiders
- 3.08%
- % Held by Institutions
- 28.92%
- RVOL
- 0.09x
- Beta
- -0.39
Pipeline stages · 2 programs
KIO-104
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
100 μg KIO-301, 50 μg KIO-301
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | KIO-104orphan | Macular Edema | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 2 | 100 μg KIO-301, 50 μg KIO-301 | Retinitis Pigmentosa | — | recruiting |
Catalyst news & presentations · 1
- next yeartrial initiationsecondaryPhase 2KIO-301 · Dosing of first patient expected to begin in 2025 after endpoint validation.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $12 (+374% upside) · 1 analysts
- 2025-09-02HC Wainwright & Co.Buy
- 2025-03-28HC Wainwright & Co.Buy
- 2024-11-12HC Wainwright & Co.Buy
- 2024-08-22HC Wainwright & Co.Buy
- 2024-07-23HC Wainwright & Co.Buy
Competitors — Retinitis Pigmentosa
Recent news
- 2026-07-18Price to sales forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView
- 2026-07-11Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5 - TradingView
- 2026-07-05Price to book forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
- 2026-07-02Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium - TMX Newsfile
- 2026-07-02[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
- 2026-07-02Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations - Stock Titan
- 2026-07-02Kiora set for Piper Sandler fireside chat on July 9 - Stock Titan
- 2026-06-26KPRX Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.